Supernus Pharmaceuticals, Inc.
SUPN
$32.22
$0.872.78%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.94% | 6.79% | -0.61% | -10.64% | -8.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.94% | 6.79% | -0.61% | -10.64% | -8.95% |
| Cost of Revenue | -7.01% | -17.99% | -21.34% | -17.38% | -3.95% |
| Gross Profit | 11.49% | 10.91% | 2.98% | -9.55% | -9.70% |
| SG&A Expenses | -0.32% | 1.79% | -6.21% | -9.42% | -10.83% |
| Depreciation & Amortization | -5.35% | -1.48% | 1.40% | 0.74% | -0.30% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.98% | 1.11% | -4.36% | -4.86% | -4.42% |
| Operating Income | 361.51% | 132.63% | 130.56% | -87.90% | -70.62% |
| Income Before Tax | 3,434.49% | 96.32% | 40.77% | -110.91% | -95.44% |
| Income Tax Expenses | 1,552.10% | 13.00% | 292.02% | 217.40% | 4,440.63% |
| Earnings from Continuing Operations | 5,512.84% | 133.05% | -87.91% | -129.80% | -97.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5,512.84% | 133.05% | -87.91% | -129.80% | -97.83% |
| EBIT | 361.51% | 132.63% | 130.56% | -87.90% | -70.62% |
| EBITDA | 44.79% | 30.94% | 23.69% | -30.97% | -25.08% |
| EPS Basic | 5,171.26% | 128.26% | -88.33% | -129.51% | -97.75% |
| Normalized Basic EPS | 260.25% | 120.97% | 113.01% | -75.03% | -64.96% |
| EPS Diluted | 14,025.26% | 168.90% | -87.91% | -133.17% | -100.92% |
| Normalized Diluted EPS | 275.60% | 157.95% | 168.81% | -71.85% | -61.99% |
| Average Basic Shares Outstanding | 1.03% | 0.91% | 1.04% | 1.33% | 1.63% |
| Average Diluted Shares Outstanding | -1.34% | -4.70% | -5.48% | -8.69% | -5.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |